Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix

Indian Journal of Physiology and Pharmacology

Volumn 46, Issue 4, 2002, Pages 423-433

  Ray, A ^a   Naik, S L D ^a   Sharma, B K ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Breast cancer; c erbB 2 oncoprotein; Cervical cancer; EGF R

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEQUENCE HOMOLOGY; UTERINE CERVIX CARCINOMA; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; UTERUS CANCER;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; UTERINE NEOPLASMS;

EID: 0036790754     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. National Cancer Registry Programme, Biennial Report, Indian Council of Medical Research, New Delhi, 1988-1989.
2. Sharma BK, Ray A, Murthy NS. Prevalence of serum antibodies to synthetic peptides to HPV16 epitopes among Indian women with cervical neoplasia. Eur J Cancer 1996; 32A: 872-876.
3. Jain D, Ray A, Bahadur AK, Chaturvedi KU, Sood R, Sharma S, Naik SLD, Sharma BK. Status of epidermal growth factor receptors family in hormone-dependent carcinomas of the breast and prostate with reference to serum lipids and lipoproteins. Indian J Clin Biochem 2001; 16: 42-51.
4. Tomatis L (Ed). Endogenous hormones, reproductive factors and sexual behaviour. In, Cancer: causes, occurrence and control. IARC (WHO) Scientific Publication, Lyon 1990: 243.
5. Sharma BK, Ray A. Breast and prostate cancer. Indian J Clin Biochem 2000; 15(Suppl.): 110-117.
6. Konda I, Shimizu N. Mapping of the human gene for epidermal growth factor receptor (EGFR) and the p13q22 region of chromosome 7. Cytogenet Cell Genet 1983; 35: 9-14.
7. Ushiro H, Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor activated protein kinase in A-431 cell membranes. J Biol Chem 1980; 25: 8363-8365.
8. International Federation of Gynecology and Obstetrics. Staging announcement: FIGO staging of gynecologic cancers: cervical and vulva. Int J Gynecol Cancer 1995; 5: 319.
9. Bloom HJC, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Surg 1957; 11: 359-377.
10. Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma: A reproducibility study. Cancer 1994; 73: 2765-2770.
11. Ratnakar N, Sharma BK, Chaturvedi KU, Kaur S, Naik SLD, Ray A. Immunohistochemical expression of c-erbB-2 oncoprotein and FGF-R in pre- and postmenopausal breast cancer. APMIS 1998; 106: 1075-1080.
12. Jardines L, Weiss M, Fowble B, Greene M. neu (c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiol 1993; 61: 268-282.
13. Maruo T, Yamasaki M, Ladines-Llave CA, Mochizuki M. Immunohistochemical demonstration of elevated expression of epidermal growth factor receptor in the neoplastic changes of cervical squamous epithelium. Cancer 1992; 69: 1182-1187.
14. Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993; 46: 149-153.
15. Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B. Over-expression of the EGF receptor is a hall mark of squamous cell carcinomas. J Pathol 1986; 149: 9-14.
16. Lakshmi S, Nair MB, Jayaprakash PG, Rajalekshmy TN, Nair MK, Pillai MR. c-erbB-2 oncoprotein and epidermal growth factor receptor in cervical lesions. Pathobiology 1997; 65: 163-168.
17. Bhadauria M, Ray A, Grover RK, Sharma S, Naik SLD, Sharma BK. Oncoprotein c-erbB-2 in squamous cell carcinoma of the uterine cervix and evaluation of its significance in response of disease to treatment. Indian J Physiol Pharmacol 2001; 45: 191-198.
18. Brumm C, Reviere A, Wilckens C, Loning T. Immunohistochemical investigation and Northern Blot analysis of c-erbB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. Virchows Archiv A Pathol Anat 1990; 417: 477-484.
19. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva and vagina. Obstet Gynecol 1990; 76: 381-387.
20. Hale RJ, Buckley CH, Fox H, Williams J. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol 1992; 45: 594-596.
21. Oka K, Nakano T, Arai T. c-erbB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994; 73: 668-671.
22. Nakano T, Oka K, Ishikawa A, Mortia S. Correlation of cervical carcinoma c-erbB-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997; 79: 513-520.
23. Perez R, Pascual M, Macias A, Lage A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat 1984; 4: 189-193.
24. Ioachim E, Kamina S, Athanassiadou S, Agnahtis NJ. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Anticancer Res 1996; 16: 3141-3147.
25. Sainsbury JRC, Farndon JR, Needham GK, Malcolm A, Harris AL. Epidermal growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; i: 1398-1402.
26. Battaglia F, Scambia G, Rossi S, Paniei PB, Bellantone R, Polizzi G, Querzoli P, Negrini R, Macobelli S, Crucitti F, Mancuso S. Epidermal growth factor receptor in human breast cancer: Correlation with steroid hormone receptors and axillary lymph node involvements. Eur J Cancer Clin Oncol 1988; 24: 1685-1690.
27. Sainsbury JRC, Malcolm A, Appleton D, Farndon JR, Harris AL. Presence of epidermal growth factor receptors as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 1985; 38: 1225-1228.
28. Sharma BK, Ray A, Kaur S, Gupta S. Immunohistochemical co-expression of c-erbB-2/Neu oncoprotein, altered tumour suppressor.(p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast. Indian J Exp Biol 1999; 37: 223-227.
29. 2 expression and response to treatment in metastatic breast cancer. Med Oncol 2000; 17: 22-28.
30. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Chikhlikar PR, Ghosh N, Trivedi TI. Prognostic significance of immunohistochemically localized biomarkers in state II and stage III breast cancer: a multivariat analysis. Ann Surg Oncol 2000; 7: 305-311.
31. 2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res 1993; 13: 1147-1152.
32. Maihle NJ, Kung HJ. C-erbB-2 and the epidermal growth factor: a molecule with dual identity. Biochim Biophys Acta 1988; 948: 287-304.
33. Perren TJ. C-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 1991; 68: 328-332.
34. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 2359-2365.
35. Ravdin PM. Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol 1999; 26(Suppl 12): 117-123.
36. Hung MC, Lau YK. Basic science of HER-2/new: a review. Semin Oncol 1999; 26(Suppl 12): 51-59.
37. Weiner LM. Monoclonal antibody therapy of cancer. Semin Oncol 1999; 26(Suppl 14): 43-51.
38. Wiechen K, Zimmer C, Dietel M. Selection of a high activity c-ErbB-2 ribozyme using a fusion gene of c-ErbB-2 and the enhanced green fluorescent protein. Cancer Gene Ther 1998; 5: 45-51.
39. Zhang L, Hung MC. Sensitization of HER-2/neu-over-expressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 1996; 12: 571-576.
40. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 1994; 29: 127-138.